MRNA
−$1.33M
10,642 sh @ $125
Bancel Stephane
Director, Chief Executive Officer · SEC CIK 1443340Advertisement
Buy track record
How this insider's open-market purchases have performed100%
of buys now in profit
2 up · 0 down
Avg return since buy+64.9%
Median return+64.9%
Best trade+64.9%
Worst trade+64.9%
Buys scored2
Average return by holding period — separates good entry timing from riding one long winner
After 1 month
−15.0%
0% won · 2 trades
After 3 months
−8.1%
0% won · 2 trades
After 6 months
−20.5%
0% won · 2 trades
After 12 months
+64.6%
100% won · 2 trades
| Date | Company | 90d trend | Buy price | Value | ΔOwn | 1M | 3M | 6M | 12M | To date |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | MRNA | $31 | $3.19M | +1.1% | −15.0% | −8.1% | −20.5% | +64.6% | +64.9% | |
| Mar 3, 2025 | MRNA | $32 | $1.81M | +0.6% | −15.0% | −8.1% | −20.5% | +64.6% | +64.9% |
How this is calculated. We score only open-market purchases (SEC code
P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 2 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$5M
2 trades
Open-market sells
$339.71M
243 trades
Net flow
−$334.71M
Net selling
Total filings
309
transactions shown
Full transaction history
All Form 4 activity across every company, newest firstMRNA
−$2.63M
20,848 sh @ $126
MRNA
−$1.08M
8,510 sh @ $127
MRNA
+$39.6K
40,000 sh @ $1
MRNA
−$2.75M
22,215 sh @ $124
Advertisement
MRNA
−$2.17M
17,396 sh @ $125
MRNA
−$48.7K
389 sh @ $125
MRNA
+$39.6K
40,000 sh @ $1
MRNA
−$4.51M
35,872 sh @ $126
MRNA
−$522.2K
4,128 sh @ $127
MRNA
+$39.6K
40,000 sh @ $1
MRNA
−$177.6K
1,410 sh @ $126
MRNA
−$1.1M
8,611 sh @ $128
MRNA
−$3.84M
29,979 sh @ $128
MRNA
+$39.6K
40,000 sh @ $1
MRNA
−$1.19M
9,478 sh @ $125
MRNA
−$1.85M
14,636 sh @ $127
MRNA
−$1.41M
11,036 sh @ $128
MRNA
−$622.8K
4,850 sh @ $128
MRNA
+$39.6K
40,000 sh @ $1
MRNA
−$1.31M
10,367 sh @ $126
MRNA
−$2.63M
20,641 sh @ $127
MRNA
−$1.11M
8,654 sh @ $128
MRNA
−$43.6K
338 sh @ $129
MRNA
+$39.6K
40,000 sh @ $1
MRNA
−$3.69M
28,144 sh @ $131
MRNA
−$1.3M
9,820 sh @ $132
MRNA
−$270.6K
2,036 sh @ $133
MRNA
+$39.6K
40,000 sh @ $1
MRNA
−$3.52M
28,476 sh @ $124
Frequently asked questions
How is Bancel Stephane's win rate calculated?
We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.
Why are some buys not included in the score?
A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.
What do the 1M / 3M / 6M / 12M columns mean?
They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.
Does a high win rate mean I should copy this insider?
No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.
Where does this data come from?
Trades come from Bancel Stephane's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.